What is Blau Syndrome?

Blau Syndrome is a rare genetic disorder characterized by inflammatory arthritis, uveitis (eye inflammation), and skin rash. It is caused by mutations in the NOD2 gene.

How big is the Blau Syndrome Market?

The global Blau Syndrome Market size was estimated at USD 7.9 Million in 2023 and is expected to reach USD 25.0 Million in 2033.

What is the Blau Syndrome Market growth?

The global Blau Syndrome Market is expected to grow at a compound annual growth rate of 12.2%. From 2024 To 2033

Who are the key companies/players in the Blau Syndrome Market?

Some of the key players in the Blau Syndrome Markets are Pfizer, Salix Pharmaceuticals, Novartis AG, Mylan N.V, Himca pharma plc, ONCODESIGN, Amgen Inc, Abbvie Inc, Alkem labs, Accord healthcare, Zydus Pharmaceuticals, Centogene AG, Teva Pharmaceuticals, Amneal Pharmaceutical Inc.

What factors contribute to the prevalence of Blau Syndrome?

The prevalence of Blau Syndrome is influenced by genetic predisposition, with the condition typically inherited in an autosomal dominant pattern. However, sporadic cases can also occur.

How is Blau Syndrome diagnosed?

Diagnosis of Blau Syndrome typically involves a thorough clinical evaluation, genetic testing to identify mutations in the NOD2 gene, and imaging studies to assess joint and ocular inflammation.

What treatment options are available for Blau Syndrome?

Treatment approaches for Blau Syndrome aim to manage symptoms and may include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents targeting inflammatory pathways.

Global Blau Syndrome Market by Therapeutic Areas (Skin Rash, Inflammation), By Route of Administration (Oral, Parenteral, Topical), By End User (Hospitals, Home healthcare, Specialty clinics), By Distribution Channel (Hospital pharmacy, Online pharmacy, Retail pharmacy), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: March 2024
Report ID: 74392
Number of Pages: 332
Format:

Overview
Table of Contents
Major Market Players
Request a Free Sample

- Pfizer
- Salix Pharmaceuticals
- Novartis AG
- Mylan N.V
- Himca pharma plc
- ONCODESIGN
- Amgen Inc
- Abbvie Inc
- Alkem labs
- Accord healthcare
- Zydus Pharmaceuticals
- Centogene AG
- Teva Pharmaceuticals
- Amneal Pharmaceutical Inc